

LRRK2 and *RIPK2* Variants in the *NOD* 2-Mediated Signaling Pathway Are Associated with Susceptibility to *Mycobacterium leprae* in Indian Populations

Patrick Marcinek^{1,9}, Aditya Nath Jha^{2,9}, Vidyagouri Shinde^{3,9}, Arun Sundaramoorthy⁴, Raja Rajkumar², Naveen Chandra Suryadevara³, Sanjeev Kumar Neela³, Hoang van Tong¹, Vellingiri Balachander⁴, Vijaya Lakshmi Valluri^{3,¶}, Kumarasamy Thangaraj^{2,¶}, Thirumalaisamy P Velavan^{1,*¶}

1 Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany, **2** CSIR-Centre for Cellular and Molecular Biology, Hyderabad, India, **3** LEPR- Blue Peter Public Health and Research Centre, Hyderabad, India, **4** Department of Zoology, School of Life sciences, Bharathiar University, Coimbatore, India

Abstract

In recent years, genome wide association studies have discovered a large number of gene loci that play a functional role in innate and adaptive immune pathways associated with leprosy susceptibility. The immunological control of intracellular bacteria *M. leprae* is modulated by NOD2-mediated signaling of Th1 responses. In this study, we investigated 211 clinically classified leprosy patients and 230 ethnically matched controls in Indian population by genotyping four variants in *NOD2* (rs9302752A/G), *LRRK2* (rs1873613A/G), *RIPK2* (rs40457A/G and rs42490G/A). The *LRRK2* locus is associated with leprosy outcome. The *LRRK2* rs1873613A minor allele and respective rs1873613AA genotypes were significantly associated with an increased risk whereas the *LRRK2* rs1873613G major allele and rs1873613GG genotypes confer protection in paucibacillary and leprosy patients. The reconstructed GA haplotypes from *RIPK2* rs40457A/G and rs42490G/A variants was observed to contribute towards increased risk whereas haplotypes AA was observed to confer protective role. Our results indicate that a possible shared mechanisms underlying the development of these two clinical forms of the disease as hypothesized. Our findings confirm and validates the role of gene variants involved in *NOD2*-mediated signalling pathways that play a role in immunological control of intracellular bacteria *M. leprae*.

Citation: Marcinek P, Jha AN, Shinde V, Sundaramoorthy A, Rajkumar R, et al. (2013) *LRRK2* and *RIPK2* Variants in the *NOD* 2-Mediated Signaling Pathway Are Associated with Susceptibility to *Mycobacterium leprae* in Indian Populations. PLoS ONE 8(8): e73103. doi:10.1371/journal.pone.0073103

Editor: Jörg Hermann Fritz, McGill University, Canada

Received: June 26, 2013; **Accepted:** July 24, 2013; **Published:** August 28, 2013

Copyright: © 2013 Marcinek et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was funded by fortune grant (1916-1-1), DFG PA 1974/3-1 and BMBF IND 10/A18 to Velavan TP. This study was also funded by LEPR- BPHRC institutional grant and by ICMR (5/8/3(13)/2009-ECD-I (A) grant to Valluri VL. This work was supported by the Council of Scientific and Industrial Research, New Delhi (www.csir.res.in) to KT. The authors acknowledge the support by the Deutsche Forschungsgemeinschaft (DFG) and Open Access Publishing Fund of Tübingen University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: velavan@medizin.uni-tuebingen.de

9 These authors contributed equally to this work.

¶ These authors also contributed equally to this work.

Introduction

Leprosy is a chronic infectious disease of the skin and nerves, caused by the bacterium *Mycobacterium leprae*. Despite decreased prevalence in last two decades, the number of new case detection rates remains high as far as in 130 countries, with India contributing to half of the new cases detected worldwide [1]. Host immune responses [2,3] and genetic factors had been shown to influence the clinical spectrum of leprosy [4–7]. Most notable is inter individual variability in disease development, with a wide range of manifestations ranging from lepromatous to tuberculoid leprosy [8]. The lepromatous leprosy is distinguished as borderline lepromatous (BL) and lepromatous (LL) forms and is classified as multibacillary (MB) based on the bacillary load, whereas the tuberculoid leprosy is distinguished as tuberculoid (TT) and borderline tuberculoid (BT) and are classified as paucibacillary (PB) by WHO standards. A difference in immune responses between multibacillary and paucibacillary forms are predicted. In multibacillary or lepromatous forms, the absence of Th1 responses

increases the bacilli load with strong humoral immunity [4]. On the other hand, the paucibacillary or the tuberculoid forms reveal an increased Th1 response with limited bacterial load.

The intracellular *M. leprae* has an extended incubation period for up to 30 years. The pathogen driven selection can potentially alter the primed sequence and can direct to substantial changes in gene expression [9]. The pathogen recognition receptors such as *TLRs* (Toll-like receptors) ably recognize the microbes at cell surfaces, whereas *PRRs* such as nucleotide oligomerization domain (*NOD*) like receptors that are localized in the cytosol can sense and recognize the intracellular pathogens [10]. A recent genome wide study in Chinese leprosy patients has provided vital insights on the role of *NOD2* (rs9302752A/G), *LRRK2* (rs1873613A/G) and *RIPK2* (rs40457A/G and rs42490G/A) variants in regulating the leprosy infection [7]. In addition, the expression of these genes has been shown to up regulate in leprosy in comparison to normal tissues [11]. The Nucleotide-binding oligomerization domain 2 (*NOD2*) located on the long arm of chromosome 16

(16q21) is an intracellular microbial sensor for muramyl dipeptide, a component of bacterial peptidoglycan [12]. Dysregulation in *NOD2* signalling is associated with pathogenesis of many inflammatory disorders [13] and is also associated with triggering of *IL-32* dependent dendritic cell programming in leprosy [14]. The cytosolic pattern recognition receptor *NOD1* and *NOD2* also activates the *RIPK2* gene [15]. The gene encoding receptor-interacting serine-threonine kinase 2 (*RIPK2*) located on the long arm of chromosome 8 (8q21) is essential for signaling through the Toll-like receptors [15,16]. In addition, the *RIPK2* interaction with *NOD2* enhances NF- κ B activity making it an important player in cellular immune response [17]. The Leucine-rich repeat serine/threonine-protein kinase 2 (*LRRK2*) variants located on the long arm of chromosome 12 (12q12) are well documented as a common cause for parkinson disease [18]. Also *LRRK2* gene variants were also documented for their role in inflammatory diseases [19] and to microbial infections [20,21]. During onset of early leprosy infection, *M. leprae* antigens are presented to CD4⁺T cells, which activate the Th1 responses resulting in interferon gamma production leading to macrophages maturation and subsequent killing. *NOD2* and *RIPK2* regulate the interferon- gamma production [7].

Initiation of *NOD2* signalling is mediated by *RIPK2* by an ubiquitination process and involvement of TAK1 and nuclear factor- κ B essential modulator to the *NOD2*-*RIPK2* complex leads to the movement of NF- κ B to the nucleus and subsequent activation of NF- κ B target genes [22]. *NOD2*-mediated signaling pathway plays an essential role in the immunological control of intracellular bacteria. We investigated the possible association of gene variants *NOD2* (rs9302752A/G), *LRRK2* (rs1873613A/G) and *RIPK2* (rs40457A/G and rs42490G/A) that are vital for *NOD2* signalling and subsequent activation of the NF- κ B complex in a cohort of clinically classified leprosy patients.

Materials and Methods

Ethical Statement

Informed written consent was received from all leprosy patients. The study was approved by the research advisory committee and institutional ethical committee of LEPROA- Blue peter public health research centre, Hyderabad, India. Informed written consent was also obtained from all the normal individuals and the institutional ethical committee of CCMB has approved this study.

Sampling

All the leprosy patients studied (n = 211) were outpatients and were recruited at the LEPROA- Blue Peter Public Health and Research Centre (BPHRC) in Hyderabad, India [23]. Patients were clinically evaluated and graded by the physicians either as a paucibacillary (PB, n = 74) or multibacillary (MB, n = 137) group, based on WHO standards [24]. Based on the number of lesions and presence of acid-fast bacilli (AFB) in skin slit smears taken from at least five different places of the body (both earlobes, both halves of the forehead, at least one from one of the lesions) leprosy patients were classified. More than five lesions as well as presence of acid fast bacilli in any of the smears precludes a multibacillary diagnosis, while a number of less than five lesions and, more importantly, a lack of acid fast bacilli in any of the smears is considered as the paucibacillary presentation. In addition to the patients, blood samples from individual controls (n = 230) were collected from adult males and females (18–35 years) from the same ethnicity.

Genotyping

DNA was isolated from blood utilizing the DNeasy Blood and Tissue kit (Qiagen, Germany) following the protocol of the manufacturer. The primer sequences utilized for genotyping with primer specific annealing temperatures is summarized in Table 1. In brief: PCR was carried out in a 20 μ l reaction volume with 5 ng of genomic DNA, 1 \times PCR buffer (20 mM Tris-HCl pH 8.4, 50 mM KCl, 1.5 mM of MgCl₂; Qiagen), 0.125 mM of dNTPs, 0.5 mM of each primer and 1 U Taq DNA polymerase (Qiagen, Hilden, Germany) on a PTC-200 Thermal cycler (MJ Research, USA). Thermal cycling parameters for amplification were: initial denaturation at 94°C for 5 min, followed by 35 cycles of respectively 15 sec at 94°C for denaturation, 60 sec at primer specific annealing temperature, and 60 sec at 72°C extension. This was followed by a final extension of 10 min at 72°C. PCR products were cleaned up using Exo-SAP-IT (USB, Affymetrix, USA) and 1 μ l of the purified product were directly used as templates for sequencing, using the BigDye terminator v. 2.0 cycle sequencing kit (Applied Biosystems, USA) on an ABI 3130 XL and ABI 3730xL DNA sequencer, according to the manufacturer's instructions. Polymorphisms were identified by assembling the sequences with respective reference sequences obtained from SNPper database (<http://snpper.chip.org>) using Codon code Aligner 4.0 software (<http://www.codoncode.com/>) and were reconfirmed visually from their respective electropherograms.

Statistical Analysis

Data was analyzed using STATA and the level of significance was set to a p-value of <0.05. The distribution of genotypes between control and leprosy patients, as well as between controls and clinically classified patients were analyzed by two tailed fisher exact tests. Genotype or haplotype frequencies were analyzed by simple gene counting and expectation-maximum (EM) algorithm and the significance of deviations from Hardy-Weinberg equilibrium was tested using the random-permutation procedure as implemented in the Arlequin v. 3.5.1.2 software. (<http://lgb.unige.ch/arlequin>). The comparison of Linkage disequilibrium (LD) for *RIPK2* variants for each patient group as well as for controls were computed using the Haploview v4.2 software that utilizes a default algorithm and this algorithm ignores markers with minor allele frequencies (MAF) <0.05.

Results

The observed distribution of genotypes and alleles in both clinically classified patients and controls were summarized in Table 2. The observed genotype and allele frequencies of all studied SNPs in clinically classified patient groups and controls were in Hardy-Weinberg equilibrium ($P > 0.05$) except for the *NOD2* SNP rs9302752 ($P < 0.05$). Therefore the *NOD2* SNP rs9302752 was excluded for further association analysis.

In *LRRK2* gene locus, we observed that the minor allele *LRRK2* rs1873613A and homozygous genotype rs1873613AA were more frequent in leprosy patients than in controls conferring an increased risk of leprosy (OR = 1.7, 95% CI = 1.25–2.2, $P = 0.0003$ and OR = 2.04, 95% CI = 1.2–3.6, $P = 0.007$, respectively). Whereas major allele *LRRK2* rs1873613G and homozygous genotype rs1873613GG were observed less frequently in patients compared to controls conferring a decreased risk of leprosy (OR = 0.61, 95% CI = 0.45–0.8, $P = 0.0003$ and OR = 0.56, 95% CI = 0.37–0.83, $P = 0.0028$, respectively). When clinically classified paucibacillary (PB) patients were compared to controls, a similar trend was observed with a stronger significance (for the minor allele rs1873613A: OR = 2.77, 95% CI = 1.9–4.1,

Table 1. Investigated SNP variants in leprosy patients and controls.

SNP ID	Locus	Gene	SNP	Primer Pairs (5'-3')	Tm [°C]
rs9302752	16q21	<i>NOD2</i>	A/G	F: GCCTTTGTTTTTCGACAGTTCCTTCAG R: CCTCGGTGACCACTTCTCTGCATTC	55
rs1873613	12q21	<i>LRRK2</i>	A/G	F: CACCCAAGACACACAAGGAAAAGCATATA R: GCCTTCTTACGTTTTTACCTCCCTCTT	55
rs40457	8q21	<i>RIPK2</i>	A/G	F: GATTTTCCCCCAGAAGAAGG R: GCAGGAAAATGAATCCATGA	50
rs42490	8q21	<i>RIPK2</i>	G/A	F: ACCCACTTCTCCCTACCACAATCTG R: GCGGAATAGCTGGATCTCTCACACA	55

doi:10.1371/journal.pone.0073103.t001

$P < 0.0001$; for the homozygous genotype *rs1873613AA*: OR = 4.1, 95% CI = 2.1–7.9, $P = P < 0.0001$). These results may confer that the *LRRK2 rs1873613A/G* contributed to the progression of paucibacillary leprosy. However, there was no significant difference of allele and genotype frequencies in comparison to multibacillary (MB) patients with controls (Table 2). In addition, we did not observe any significant difference of heterozygous genotype frequency in all comparisons.

Two loci of *RIPK2* gene (*rs40457A/G* and *rs42490G/A*) were investigated in this study. However, no significant difference of allele and genotype frequency of neither SNP *rs40457A/G* or *rs42490G/A* was observed in all the comparisons. In leprosy patients, both the studied *RIPK2* variants were observed to be in high LD [Leprosy patients ($D' = 0.64$, LOD = 12.72, $r^2 = 0.2$), MB patients ($D' = 0.53$, LOD = 5.84, $r^2 = 0.56$), PB patients ($D' = 0.84$, LOD = 7.58, $r^2 = 0.34$)], whereas in controls it was observed in a low degree of linkage disequilibrium ($D' = 0.38$, LOD = 3.2, $r^2 = 0.06$). We reconstructed haplotype based on these two studied *RIPK2* SNPs (*rs40457A/G* and *rs42490G/A*). Four haplotypes and their frequencies were observed including *AG*, *AA*, *GA* and *GG*. The *RIPK2* haplotype *GA* was observed more frequently in leprosy patients compared to controls inferring an increased risk of leprosy (OR = 1.46, 95% CI = 1.02–2.1, $P = 0.036$), whereas *RIPK2* haplotype *AA* was observed less frequently in leprosy patients compared to controls inferring a protection against leprosy (OR = 0.69, 95% CI = 0.49–0.97, $P = 0.028$). In addition, *RIPK2* haplotype *GA* was observed more frequently in paucibacillary (PB) patients in comparison to controls inferring an increased risk of leprosy (OR = 1.8, 95% CI = 1.1–2.8, $P = 0.018$). Furthermore, there was no significant difference of *RIPK2* haplotype frequencies in comparison between multibacillary (MB) patients with controls (Table 3).

Discussion

All the four studied innate immune gene variants were hypothesized to play a significant role in controlling the interferon-gamma production and considered as vital modulators for NF- κ B [7]. We investigated the role of gene variants in *NOD2* (*rs9302752A/G*), *LRRK2* (*rs1873613A/G*) and *RIPK2* (*rs40457A/G* and *rs42490G/A*) based on a recently published genome-wide association study (GWAS) that utilized Han Chinese population [7]. Although the studied sample size was lower, the frequencies of all four studied variants were in accordance with Han Chinese population and also in a Gujarati Indian population as reported in HapMap database. The minor allele of *NOD2 rs9302752A/G* variant was observed at a similar frequency (0.28) in the studied

Indian population to reported frequencies in Han Chinese population (0.22). However, the *NOD2 rs9302752A/G* variant was not in Hardy-Weinberg equilibrium in Indian clinically classified leprosy patients and marginally significant in control group. The major allele of *LRRK2 rs1873613A/G* variant was also observed at a similar frequency (0.68) compared to reported frequencies in Gujarati Indians in Houston, Texas (GIH) (0.61) as reported in the NCBI Hapmap database. The minor allele of studied *RIPK2* variant *rs40457A/G* was observed at a similar frequency (0.21) when compared to reported frequencies in Han Chinese (0.25) and in Gujarati Indians in Houston, Texas (GIH) (0.30), whereas the minor allele of *RIPK2 rs42490A/G* was observed at a similar frequency (0.41) when compared to reported frequencies in Han Chinese (0.45) and in Gujarati Indians in Houston, Texas (GIH) (0.40).

NOD2 is an intracellular microbial sensor of the innate immune system that can act as a potent activator and regulator of inflammation in mycobacterial infections [10,25]. Mutations in the gene encoding *NOD2* in humans have been associated with Crohn's disease (CD) [26], Blau syndrome (BS) [27], and early onset sarcoidosis (EOS) [28]. In addition, the studied *NOD2* variant (*rs9302752A/G*) was associated with susceptibility to tuberculosis and leprosy in Chinese and Vietnamese population [7,29,30]. *NOD2* signaling pathways are activated by a CARD effector domain that causes inflammation by the activation of NF- κ B and MAP kinase pathways [10]. Studies have documented the fact that stimulation of NOD proteins are associated with enhanced pro inflammatory cytokine production to *M. leprae* infections [31] and this is well achieved by the recognition of conserved microbial domains by PRRs. Therefore, any alteration in the gene function of PRR domain may possibly reflect towards leprosy susceptibility. Also it was shown that phenotypes of mouse deficient with *NOD2* and *RIPK2* revealed a failure to produce inflammatory cytokines to initiate Th1 responses [32]. In contrast to Han Chinese population [7] we observed that *NOD2 rs9302752A/G* variant was not in Hardy-Weinberg equilibrium in studied Indian population, therefore the contribution of this variant to leprosy susceptibility remains unclear. The possibilities for the studied *NOD2* variant not in HWE can be due to the fact that Indian populations have been following strict endogamy marriage practices for last tens of thousands years, hence every population acquired unique set of genetic variations. In this study, the leprosy patients represent different ethnic groups from south India and the number from each group is very less. Nevertheless in this study, we always employed ethnically matched control individuals from the same population to avoid the role of

Table 2. Distribution of investigated *MOD2*, *RIPK2*, and *LRRK2* variants in clinically classified leprosy patients and controls.

Loci	Patients n = 211(%)		MB (LL+LB) n = 137(%)		LL n = 62 (%)		LB n = 75 (%)		PB (BT+TT) n = 74 (%)		BT n = 70 (%)		TT n = 4 (%)		Controls n = 230 (%)		Patients vs. Controls OR (95% CI)		MB vs. Controls OR (95% CI)		PB vs. Controls OR (95% CI)		P value	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	P value	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)		
<i>MOD2_rs9302752</i>																								
AA	120	(56.9)	84	(61.3)	52	(83.9)	32	(42.7)	36	(48.6)	34	(48.6)	2	(5.0)	114	(49.6)	NA	NA	NA	NA	NA	NA	NA	NA
AG	58	(27.5)	32	(23.4)	9	(14.5)	23	(30.7)	26	(35.1)	25	(35.7)	1	(2.5)	104	(45.2)	NA	NA	NA	NA	NA	NA	NA	NA
GG	33	(15.6)	21	(15.3)	1	(1.6)	20	(26.6)	12	(16.2)	11	(15.7)	1	(2.5)	12	(5.2)	NA	NA	NA	NA	NA	NA	NA	NA
A	298	(70.6)	200	(73)	113	(91)	87	(58)	98	(66.2)	93	(66.4)	5	(62.5)	332	(72.2)	NA	NA	NA	NA	NA	NA	NA	NA
G	124	(29.4)	74	(27)	11	(9)	63	(42)	50	(33.8)	47	(35.6)	3	(37.5)	128	(27.8)	NA	NA	NA	NA	NA	NA	NA	NA
<i>LRRK2_rs1873613</i>																								
GG	73	(34.6)	56	(40.9)	27	(43.6)	29	(38.7)	17	(23)	16	(22.8)	1	(2.5)	112	(48.7)	0.56	(0.37–0.83)	0.0028	NS	0.31	(0.16–0.6)	0.0001	
AG	93	(44.1)	62	(45.2)	25	(40.3)	37	(49.3)	31	(41.9)	30	(42.9)	1	(2.5)	91	(39.6)	NS	NS	NS	NS	NS	NS	NS	NS
AA	45	(21.3)	19	(13.9)	10	(16.1)	9	(12)	26	(35.1)	24	(34.3)	2	(5.0)	27	(11.7)	2.04	(1.2–3.6)	0.007	NS	4.1	(2.1–7.9)	0.000014	
G	239	(56.6)	174	(63.5)	79	(63.7)	95	(63.3)	65	(43.9)	62	(44.3)	3	(37.5)	315	(68.5)	0.61	(0.45–0.8)	0.0003	NS	0.36	(0.240.54)	0.00000017	
A	183	(43.4)	100	(36.5)	45	(36.3)	55	(36.7)	83	(56.1)	78	(55.7)	5	(62.5)	145	(31.5)	1.7	(1.25–2.2)	0.0003	NS	2.77	(1.9–4.1)	0.00000017	
<i>RIPK2_rs40457</i>																								
AA	117	(54.5)	77	(56.2)	32	(51.6)	45	(60)	40	(54)	37	(52.9)	3	(7.5)	144	(62.6)	NS	NS	NS	NS	NS	NS	NS	NS
AG	79	(37.4)	50	(36.5)	25	(40.3)	25	(33.3)	29	(39.2)	28	(40)	1	(2.5)	74	(32.2)	NS	NS	NS	NS	NS	NS	NS	NS
GG	15	(7.1)	10	(7.3)	5	(8.1)	5	(6.7)	5	(6.8)	5	(7.1)	0	(0)	12	(5.2)	NS	NS	NS	NS	NS	NS	NS	NS
A	313	(74.2)	204	(74.5)	89	(71.8)	115	(76.7)	109	(73.6)	102	(72.9)	7	(87.5)	362	(78.7)	NS	NS	NS	NS	NS	NS	NS	NS
G	109	(23.8)	70	(25.5)	35	(28.2)	35	(23.3)	39	(26.4)	38	(27.1)	1	(12.5)	98	(21.3)	NS	NS	NS	NS	NS	NS	NS	NS
<i>RIPK2_rs42490</i>																								
GG	82	(38.9)	55	(40.1)	23	(37.1)	32	(42.7)	27	(36.5)	26	(37.1)	1	(2.5)	85	(37)	NS	NS	NS	NS	NS	NS	NS	NS
GA	90	(42.7)	59	(43.1)	23	(37.1)	36	(48)	31	(41.9)	28	(40)	3	(7.5)	104	(45.2)	NS	NS	NS	NS	NS	NS	NS	NS
AA	39	(18.4)	23	(16.8)	16	(25.8)	7	(9.3)	16	(21.6)	16	(22.9)	0	(0)	41	(17.8)	NS	NS	NS	NS	NS	NS	NS	NS
G	254	(60.2)	169	(61.7)	69	(55.6)	100	(66.7)	85	(49.2)	80	(57.1)	5	(62.5)	274	(59.6)	NS	NS	NS	NS	NS	NS	NS	NS
A	168	(39.8)	105	(38.3)	55	(44.4)	50	(33.3)	63	(50.8)	60	(42.9)	3	(37.5)	186	(40.4)	NS	NS	NS	NS	NS	NS	NS	NS

doi:10.1371/journal.pone.0073103.t002

Table 3. Distribution of investigated *RIPK2* haplotypes in clinically classified leprosy patients and controls.

<i>RIPK2</i> haplotype (<i>r</i> =40457/ <i>rs</i> 42490)	Patients n = 422 (%)								Controls n = 460 (%)		PB vs. Controls		MB vs. Controls		Patients vs. Controls		PB vs. Controls	
	MB (LL+LB) n = 274	LL n = 124	LB n = 150	PB (BT+TT) n = 148	BT n = 140	TT n = 8	Controls n = 460	(%)	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value		
AG	152 (55.5)	66 (53.2)	86 (57.3)	82 (55.4)	77 (55.0)	5 (62.5)	247 (53.7)		NS		NS		NS		NS			
AA	79 (18.7)	23 (18.6)	29 (19.3)	27 (18.3)	25 (17.9)	2 (25.0)	115 (25.0)	0.69 (0.49–0.97)	0.028		NS		NS		NS			
GA	89 (21.1)	32 (25.8)	21 (14.0)	36 (24.3)	35 (25.0)	1 (12.5)	71 (15.4)	1.46 (1.02–2.1)	0.036		NS		NS	1.8 (1.1–2.8)	0.018			
GG	20 (4.7)	3 (2.4)	14 (9.4)	3 (2.0)	3 (2.1)	0	27 (5.9)		NS		NS		NS		NS			

doi:10.1371/journal.pone.0073103.t003

population stratification in allelic difference between cases and controls.

For the investigated *LRRK2* rs1873613A/G variant the contribution was observed of this particular variant in the studied Indian population. The minor allele *A* and homozygous genotype *AA* contributed towards an increased risk of leprosy whereas the major allele *G* and homozygous genotype *GG* predisposed as protective factors for leprosy. Our results also showed that *LRRK2* rs1873613A/G variant significantly contributed to the development of paucibacillary leprosy but not multibacillary leprosy. Earlier studies have demonstrated that a trend towards an association between the variant and susceptibility to leprosy [7]. The association study of *LRRK2* rs1873613A/G variant with leprosy was also conducted in a Vietnamese population, however the association was not statistically significant [30]. *LRRK2* is associated with various diseases, including Parkinson’s disease, cancer, and leprosy [33] and also known to be associated with susceptibility to the chronic autoimmune Crohn’s disease, which is an inflammatory disorder [34]. Higher expression of *LRRK2* is observed in macrophages and monocytes revealing its significance in the innate immune system [35] and in leprosy per se. Most of the replication studies do not document similar effects of a particular gene variant contribution when investigated in different ethnicities [36–38]. In the reported GWAS study from Han Chinese population, the *LRRK2* rs1873613A allele was observed as a major allele whereas the rs1873613G variant is a minor allele and confers decreased risk towards leprosy in Chinese patients. [7]. Additionally similar allele frequencies were reported in the Vietnamese population [30]. However in the studied Indian population, the *LRRK2* rs1873613G allele was observed as a major allele whereas the rs1873613A variant increased the risk towards leprosy in the investigated Indian cohort. There seems a switch of allele frequencies between populations and the clinical significance of the studied variant likely depends on the context of the studied ethnicities. Additionally India is inhabited by the very first out-of-Africa modern human about 65,000 years ago. Since then they remain unmixed, therefore the genome of Indian populations are unique and the allele frequency differ significantly when compare to the rest of the world [39]. *LRRK2* gene has been shown to play an important role in different diseases including Parkinson, Crohn’s and inflammatory diseases [18,19,21,33]. Interestingly, *LRRK2* has been also demonstrated to be an IFN-gamma target gene, involve in different immune response signaling such as NF-κB pathways, and contribute to the antibacterial activity of the macrophages, in which *LRRK2* plays a role in the killing of intracellular bacteria such as *S. typhimurium* [20]. In addition, the expression of *LRRK2* gene was significantly higher in leprosy compared to normal tissues [11]. This suggested that *LRRK2* might contribute crucially to the immune response against intracellular bacteria *M. leprae*.

The *RIPK2* rs40457A/G and rs42490G/A variants did not confer any significance results at allele and genotype levels. A larger sample size will be required in order to detect any significance for the both studied *RIPK2* variant at allele level. We observed the reconstructed haplotypes *AA* and *GA* based on two variants rs40457A/G and rs42490G/A to be significantly associated with leprosy susceptibility. In addition, the haplotype *GA* also conferred to an increased risk of paucibacillary leprosy development. Recently, a replicate study conducted in a Vietnamese population showed that the variant *RIPK2* rs42490G/A was significantly associated with leprosy whereas the significance was not revealed for the variant *RIPK2* rs40457A/G [30]. Studies have established the fact that *RIPK2* interaction with *NOD2* enhances NF-κB activity making it an important

player in cellular immune response [17]. A recent study has also documented on the interaction between the *NOD2* and *RIPK2* loci (*NOD2-RIPK2* complex) in activating the NF- κ B pathway as a part of the host defence response to leprosy infection [40]. Therefore, our results indicate that a possible shared mechanisms as a basis for the development of these two clinical forms of the disease as hypothesized earlier [7].

In conclusion, our study validated the association of gene variants involved in intracellular sensing that are believed to play a role in immunologic control of intracellular bacteria *M. leprae* in Indian leprosy patients. Overall the study increases our understanding on complex molecular and cellular mechanisms that are regulated by the intracellular pathogen *M. leprae* during its clinical course.

References

1. Leprosy update, 2011. (2011) *Wkly Epidemiol Rec* 86: 389–399.
2. Monot M, Honore N, Garnier T, Zidane N, Sherafi D, et al. (2009) Comparative genomic and phylogeographic analysis of *Mycobacterium leprae*. *Nat Genet* 41: 1282–1289.
3. Ridley DS. (1974) Histological classification and the immunological spectrum of leprosy. *Bull World Health Organ* 51: 451–465.
4. de Messias-Reason IJ, Boldt AB, Moraes Braga AC, Von Rosen Seeling SE, Dornelles L, et al. (2007) The association between mannan-binding lectin gene polymorphism and clinical leprosy: new insight into an old paradigm. *J Infect Dis* 196: 1379–1385.
5. Schurr E, Gros P. (2009) A common genetic fingerprint in leprosy and Crohn's disease? *N Engl J Med* 361: 2666–2668.
6. Vannberg FO, Chapman SJ, Hill AV. (2011) Human genetic susceptibility to intracellular pathogens. *Immunol Rev* 240: 105–116.
7. Zhang FR, Huang W, Chen SM, Sun LD, Liu H, et al. (2009) Genomewide association study of leprosy. *N Engl J Med* 361: 2609–2618.
8. Ridley DS, Jopling WH. (1966) Classification of leprosy according to immunity. A five-group system. *Int J Lepr Other Mycobact Dis* 34: 255–273.
9. Velavan TP, Buyukyazici B, Kremsner PG, Kun JF. (2012) Combined promoter haplotypes of the *IL10R* genes are associated with protection against severe malaria in Gabonese children. *Immunogenetics* 64: 87–95.
10. Borutzky A, Fried A, Chou J, Bonilla FA, Kim S, et al. (2010) *NOD2*-associated diseases: Bridging innate immunity and autoinflammation. *Clin Immunol* 134: 251–261.
11. Sun Y, Liu H, Yu G, Chen X, Liu H, et al. (2011) Gene expression analysis of leprosy by using a multiplex branched DNA assay. *Exp Dermatol* 20: 520–522.
12. Jeong YJ, Kim CH, Song EJ, Kang MJ, Kim JC, et al. (2012) Nucleotide-binding oligomerization domain 2 (*Nod2*) is dispensable for the innate immune responses of macrophages against *Yersinia enterocolitica*. *J Microbiol* 50: 489–495.
13. Tigno-Aranjuez JT, Abbott DW. (2012) Ubiquitination and phosphorylation in the regulation of *NOD2* signaling and *NOD2*-mediated disease. *Biochim Biophys Acta*.
14. Schenk M, Krutzik SR, Sieling PA, Lee DJ, Teles RM, et al. (2012) *NOD2* triggers an interleukin-32-dependent human dendritic cell program in leprosy. *Nat Med* 18: 555–563.
15. Madrigal AG, Barth K, Papadopoulos G, Genco CA. (2012) Pathogen-Mediated Proteolysis of the Cell Death Regulator *RIPK1* and the Host Defense Modulator *RIPK2* in Human Aortic Endothelial Cells. *PLoS Pathog* 8: e1002723.
16. Kim BC, Kang TJ, Jin SH, Kim SK, Lee SB, et al. (2004) Tissue-specific down-regulation of *RIPK 2* in *Mycobacterium leprae*-infected nu/nu mice. *Mediators Inflamm* 13: 51–52.
17. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, et al. (2001) *Nod2*, a *Nod1*/*Apaf-1* family member that is restricted to monocytes and activates NF- κ B. *J Biol Chem* 276: 4812–4818.
18. Lee BD, Dawson VL, Dawson TM. (2012) Leucine-rich repeat kinase 2 (*LRRK2*) as a potential therapeutic target in Parkinson's disease. *Trends Pharmacol Sci* 33: 365–373.
19. Liu Z, Lenardo MJ. (2012) The role of *LRRK2* in inflammatory bowel disease. *Cell Res* 22: 1092–1094.
20. Gardet A, Benita Y, Li C, Sands BE, Ballester I, et al. (2010) *LRRK2* is involved in the IFN- γ response and host response to pathogens. *J Immunol* 185: 5577–5585.
21. Hakimi M, Selvanantham T, Swinton E, Padmore RF, Tong Y, et al. (2011) Parkinson's disease-linked *LRRK2* is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. *J Neural Transm* 118: 795–808.

Acknowledgments

We thank all individuals who provided their blood sample and consent for genetic analysis. We would like to thank Velia Grummes for technical support.

Author Contributions

Conceived and designed the experiments: KT TPV VLV. Performed the experiments: PM ANJ VS AS NCS SKN HVT RR. Analyzed the data: HVT TPV. Contributed reagents/materials/analysis tools: VB KT TPV. Wrote the paper: PM TPV HVT.

22. Hitotsumatsu O, Ahmad RC, Tavares R, Wang M, Philpott D, et al. (2008) The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. *Immunity* 28: 381–390.
23. Shinde V, Marcinek P, Rani DS, Sunder SR, Arun S, et al. (2013) Genetic evidence of *TAP1* gene variant as a susceptibility factor in Indian leprosy patients. *Hum Immunol* 74: 803–807.
24. Shinde V, Marcinek P, Rani DS, Sunder SR, Arun S, et al. (2013) Genetic evidence of *TAP1* gene variant as a susceptibility factor in Indian leprosy patients. *Hum Immunol* 74: 803–807.
25. Ferwerda G, Girardin SE, Kullberg BJ, Le BL, de Jong DJ, et al. (2005) *NOD2* and toll-like receptors are nonredundant recognition systems of *Mycobacterium tuberculosis*. *PLoS Pathog* 1: 279–285.
26. Hugot JP, Chamallard M, Zouali H, Lesage S, Cezard JP, et al. (2001) Association of *NOD2* leucine-rich repeat variants with susceptibility to Crohn's disease. *Nature* 411: 599–603.
27. Johannsen U. (1968) [Studies of infectious enteritis (panleukopenia) in felines. I. Clinical aspects and pathological anatomy of the disease]. *Arch Exp Veterinarmed* 22: 233–246.
28. Okafuji I, Nishikomori R, Kanazawa N, Kambe N, Fujisawa A, et al. (2009) Role of the *NOD2* genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. *Arthritis Rheum* 60: 242–250.
29. Pan H, Dai Y, Tang S, Wang J. (2012) Polymorphisms of *NOD2* and the risk of tuberculosis: a validation study in the Chinese population. *Int J Immunogenet* 39: 233–240.
30. Grant AV, Alter A, Huong NT, Orlova M, Van TN, et al. (2012) Crohn's disease susceptibility genes are associated with leprosy in the Vietnamese population. *J Infect Dis* 206: 1763–1767.
31. Kang TJ, Chae GT. (2011) The Role of Intracellular Receptor *NODs* for Cytokine Production by Macrophages Infected with *Mycobacterium leprae*. *Immune Netw* 11: 424–427.
32. Moreira LO, El Kasmi KC, Smith AM, Finkelstein D, Fillon S, et al. (2008) The *TLR2-MyD88-NOD2-RIPK2* signalling axis regulates a balanced pro-inflammatory and *IL-10*-mediated anti-inflammatory cytokine response to Gram-positive cell walls. *Cell Microbiol* 10: 2067–2077.
33. Lewis PA, Manzoni C. (2012) *LRRK2* and human disease: a complicated question or a question of complexes? *Sci Signal* 5: e2.
34. Umeno J, Asano K, Matsushita T, Matsumoto T, Kiyohara Y, et al. (2011) Meta-analysis of published studies identified eight additional common susceptibility loci for Crohn's disease and ulcerative colitis. *Inflamm Bowel Dis* 17: 2407–2415.
35. Kaiser S, Di MP, Murphy ME, Sies H. (1990) Quenching of singlet molecular oxygen by tocopherols. *Adv Exp Med Biol* 264: 117–124.
36. Assaf A, Hoang TV, Faik I, Aebischer T, Kremsner PG, et al. (2012) Genetic evidence of functional *ficolin-2* haplotype as susceptibility factor in cutaneous leishmaniasis. *PLoS One* 7: e34113.
37. Hoang TV, Toan NL, Song IH, Ouf EA, Bock CT, et al. (2011) *Ficolin-2* levels and *FCN2* haplotypes influence hepatitis B infection outcome in Vietnamese patients. *PLoS One* 6: e28113.
38. Ouf EA, Ojurongbe O, Akindele AA, Sina-Agbaje OR, Van TH, et al. (2012) *Ficolin-2* Levels and *FCN2* Genetic Polymorphisms as a Susceptibility Factor in Schistosomiasis. *J Infect Dis*.
39. Reich D, Thangaraj K, Patterson N, Price AL, Singh L. (2009) Reconstructing Indian population history. *Nature* 461: 489–494.
40. Zhang F, Liu H, Chen S, Low H, Sun L, et al. (2011) Identification of two new loci at *IL23R* and *RAB32* that influence susceptibility to leprosy. *Nat Genet* 43: 1247–1251.